|
5-factor prognostic model for survival of patients with metastatic urothelial carcinoma receiving three different post-platinum PD-L1 inhibitors. |
|
|
|
Consulting or Advisory Role - Agensys; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Genentech; Janssen; Merck; Novartis; Sanofi |
Speakers' Bureau - Clinical Care Options/NCCN; Onclive; Physicans' Education Resource; Research to Practice |
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Janssen (Inst); Merck (Inst); Onyx (Inst); Pfizer (Inst); Sanofi (Inst) |
Other Relationship - Astellas Pharma; AstraZeneca; Bavarian Nordic; Boehringer Ingelheim; Bristol-Myers Squibb |
|
|
|
|
|
|
|
|
No Relationships to Disclose |
|
|
|
|
|
Honoraria - Roche Pharma AG |
Consulting or Advisory Role - Bristol-Myers Squibb; IMS Health; Roche Pharma AG |
|
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pfizer; Pfizer; Roche |
|
|
Stock and Other Ownership Interests - Illumina; Merck |
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Medscape; Peerview; UpToDate; Vindico |
Consulting or Advisory Role - Adicet Bio; Agensys; AstraZeneca/MedImmune; Bayer; BioClin Therapeutics; Bristol-Myers Squibb; EMD Serono; Fortress Biotech; Inovio Pharmaceuticals; Lilly; Merck; Pharmacyclics; QED Therapeutics; Roche/Genentech; Sanofi; Seagen; Sensei Biotherapeutics; western oncolytics |
Research Funding - Agensys (Inst); AstraZeneca; Bayer (Inst); Genentech (Inst); Genentech/Roche (Inst); Incyte; Mirati Therapeutics (Inst); Novartis (Inst); Oncogenex (Inst); Seagen (Inst); Viralytics (Inst) |
Patents, Royalties, Other Intellectual Property - Predictor of platinum sensitivity (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech/Roche |
|
|
Honoraria - Merck Sharp & Dohme |
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; EMD Serono; Fidia Farmaceutici S. p. A.; Genentech; Lilly; Lilly; Merck; Novartis; Pfizer; Roche; Roche/Genentech; Urogen pharma |
Research Funding - Amgen (Inst); Astellas Pharma; AstraZeneca; Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); dendreon (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Seattle Genetics/Astellas |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Roche/Genentech; Urogen pharma |
|
|
Consulting or Advisory Role - AstraZeneca; Biocept; Bristol-Myers Squibb; Clovis Oncology; Driver, Inc; EMD Serono; Foundation Medicine; Genentech; HERON; Janssen; Merck; Pfizer; QED Therapeutics; Seagen |
Speakers' Bureau - Bristol-Myers Squibb |
Research Funding - AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Oncogenex (Inst); Pfizer (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Eisai; Eisai; EMD Serono; Genentech/Roche; Incyte; Pfizer |
Research Funding - BioClin Therapeutics (Inst); Genentech (Inst); Janssen Oncology (Inst); Merck (Inst); Seagen (Inst) |
|
|
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech/Roche; Health Advances; Inovio Pharmaceuticals; Merck; Oncogenex; Pieris Pharmaceuticals |
Research Funding - Acerta Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Heat Biologics (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Oncogenex (Inst); Principa Biopharma (Inst) |
|
|
Stock and Other Ownership Interests - Rappta Therapeutics |
Consulting or Advisory Role - Aileron Therapeutics; Astellas Pharma; AstraZeneca; BioMotiv; Bristol-Myers Squibb; Dendreon; Dracen; EMD Serono; Genentech; GlaxoSmithKline; Incyte; Inovio Pharmaceuticals; Janssen; Lilly; Merck; Novartis; NuMab; Pfizer; Seagen |
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst) |
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792 |
|
|
|
Stock and Other Ownership Interests - Bayer (I) |
Honoraria - AstraZeneca; Foundation Medicine; Janssen; Merck; Roche |
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Incyte; Janssen; Merck Sharp & Dohme; Rainier Therapeutics; Roche; Seattle Genetics/Astellas |
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Merck Sharp & Dohme; Roche |
Other Relationship - Bayer (I) |
|
|
Consulting or Advisory Role - Genentech/Roche |
Speakers' Bureau - Genentech |
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech (Inst); Merck (Inst) |
|
|
Honoraria - AstraZeneca; Bristol-Myers Squibb; MERCK; Novartis; Pfizer; Roche/Genentech |
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Incyte; Ipsen; Merck; Novartis; Novartis; Pfizer; Seagen |
Research Funding - AstraZeneca/MedImmune; Roche/Genentech |
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis/Ipsen; Pfizer; Roche/Genentech |
|
|
|
Stock and Other Ownership Interests - AstraZeneca; Bristol-Myers Squibb |
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb |
|
|
Employment - AstraZeneca; MedImmune |
Stock and Other Ownership Interests - AstraZeneca; MedImmune |
Patents, Royalties, Other Intellectual Property - MedImmune |
|
|
Employment - Roche Canada (I) |
Stock and Other Ownership Interests - Roche Canada (I) |
Consulting or Advisory Role - Bayer; Takeda |